Singapore markets close in 6 hours 41 minutes

Bio-Rad Laboratories, Inc. (BIO)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
547.01-23.75 (-4.16%)
At close: 4:02PM EST

539.10 -7.91 (-1.45%)
After hours: 7:42PM EST

Full screen
Trade prices are not sourced from all markets
Previous close570.76
Open565.65
Bid0.00 x 800
Ask658.00 x 900
Day's range545.00 - 566.83
52-week range309.38 - 648.39
Volume160,021
Avg. volume237,093
Market cap16.332B
Beta (5Y monthly)0.82
PE ratio (TTM)4.69
EPS (TTM)116.69
Earnings date11 Feb 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est661.25
  • Bio-Rad to Report Fourth-Quarter and Full-Year 2020 Financial Results Thursday, February 11, 2021
    Business Wire

    Bio-Rad to Report Fourth-Quarter and Full-Year 2020 Financial Results Thursday, February 11, 2021

    Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the fourth quarter and full year 2020 on Thursday, February 11, 2021, following the close of the market. The company will discuss these results in a conference call scheduled for 3 PM Pacific Time (6 PM Eastern Time) that day.

  • Bio-Rad to Participate in Fireside Chat at the 39th Annual J.P. Morgan Healthcare Conference on January 11
    Business Wire

    Bio-Rad to Participate in Fireside Chat at the 39th Annual J.P. Morgan Healthcare Conference on January 11

    Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO; Andrew Last, Executive Vice President and COO; and Ilan Daskal, Executive Vice President and CFO will participate virtually in a Fireside Chat at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, at 1:30 PM (PST).

  • Bio-Rad Provides Outlook Through 2023
    Business Wire

    Bio-Rad Provides Outlook Through 2023

    Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced today its outlook through 2023, which shows the company’s commitment to continued organic growth, continued margin expansion, and its efforts on sustainability measures.